Trial comparing treatments for Prostatic Neoplasms, Castration-Resistant
Official title A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.gov ID: NCT07225946
What this study is testing
What is Pasritamig?
Pasritamig is an investigational medicine being studied for metastatic castration‑resistant prostate cancer.
Also referred to as JNJ-78278343.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see whether adding pasritamig to docetaxel delays cancer progression as seen on scans or death, compared to docetaxel alone.
- Who it's for
- It is looking for men whose prostate cancer has spread and keeps growing even after hormone therapy has lowered testosterone.
- What's involved
- Participants will receive the drug pasritamig together with docetaxel, and will have regular scans and medical visits to monitor the cancer.
- Time commitment
- The study lasts until the cancer progresses or the participant drops out, with visits and scans scheduled throughout the treatment period.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have histologically confirmed adenocarcinoma of the prostate
- Have disease that is metastatic at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m\^Tc bone scan as...
- Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or...
- Have progressed by PSA or CT/MRI or 99m\^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different...
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
You likely can't join if
- Known history of either brain or leptomeningeal prostate cancer metastases
- Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose)...
- Prior or concurrent second malignancy (other than the disease under study)
- Received cytotoxic chemotherapy for prostate cancer in any setting
- Received prior treatment with human kallikrein 2 (KLK-2) directed therapies
The study team makes the final eligibility decision.
Where it is enrolling
- Chandler, Arizona, United States
- Little Rock, Arkansas, United States
- Springdale, Arkansas, United States
- Fountain Valley, California, United States
- La Jolla, California, United States
- Los Alamitos, California, United States
- Los Angeles, California, United States
- Riverside, California, United States
- San Diego, California, United States
- Santa Monica, California, United States
- Aurora, Colorado, United States
- Denver, Colorado, United States
- Edwards, Colorado, United States
- Grand Junction, Colorado, United States
- Lakewood, Colorado, United States
- Orlando, Florida, United States
- Pembroke Pines, Florida, United States
- Sarasota, Florida, United States
- Atlanta, Georgia, United States
- Lisle, Illinois, United States
+ 122 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Chandler, Arizona, United States; Little Rock, Arkansas, United States; Springdale, Arkansas, United States; Fountain Valley, California, United States; La Jolla, California, United States; Los Alamitos, California, United States and 136 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.